Masimo Co. (NASDAQ:MASI) Receives $179.67 Consensus Target Price from Brokerages

Shares of Masimo Co. (NASDAQ:MASI) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $191.40.

A number of equities analysts have commented on the company. Raymond James lifted their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd. Wells Fargo & Company lifted their target price on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, BTIG Research lifted their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th.

Masimo Stock Up 2.3 %

Shares of Masimo stock opened at $181.70 on Friday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $9.73 billion, a P/E ratio of 125.31 and a beta of 1.01. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $183.14. The business has a 50-day moving average price of $171.00 and a 200 day moving average price of $143.75.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.63 earnings per share. On average, sell-side analysts forecast that Masimo will post 4.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Masimo

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC lifted its position in Masimo by 41.2% in the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock worth $900,860,000 after purchasing an additional 1,970,883 shares during the period. State Street Corp lifted its position in Masimo by 0.7% in the third quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock worth $191,837,000 after purchasing an additional 10,179 shares during the period. Westfield Capital Management Co. LP lifted its position in Masimo by 23.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after purchasing an additional 262,370 shares during the period. Geode Capital Management LLC lifted its position in Masimo by 1.5% in the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after purchasing an additional 11,984 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in Masimo by 9.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider’s stock worth $105,619,000 after purchasing an additional 70,440 shares during the period. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.